🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Overexcited for this piece out in The Lancet Haematology 👉 a huge collaboration on behalf of the CMWP of the The EBMT led by DrDonalMcLornan and an incredible global panel of experts: how to deal with germline predisposition in MDS undergoing HSCT. authors.elsevier.com/c/1h~Ie_rV3GEO…

Happy to announce that the TxID Special Edition on infections in patients with heme malignancies and recipients of cellular therapies is now available! Sincere thanks to all the authors for their contributions--lots of high-yield, timely information in here! Gabrielle Haeusler

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation - The Lancet Haematology thelancet.com/pdfs/journals/…

NEW from Rahul Banerjee, MD, FACP David Maloney & colleagues: Answering the "Doctor, can CAR-T therapy cause cancer?" question in clinic Blood Advances Immortal time bias = if pts don't live longer (thanks to CAR T), secondary malignancy won't be observed #cancer #immunotherapy

NEW: Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of The EBMT #bmtsm #GVHD thelancet.com/journals/lanha…

Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies #genetherapy

Dr Syed Osman Ahmed showing the disparities in access to #CART Cells across the globe during the joint #WBMT The EBMT session at #EBMT2024 Ibrahim Yakoub-Agha Mahmoud Aljurf World Health Organization (WHO)

⁦مركز الأبحاث⁩ acknowledged Kure.ai David Wald for ongoing collaborations in the Kingdom.

The meta-analysis of real-world studies of axi-cel versus tisa-cel in relapsed/refractory DLBCL finds that axi-cel significantly improves responses and progression-free survival, while tisa-cel significantly reduces higher-grade CRS and neurotoxicity. ow.ly/Q1sx50SNJ6z

Pleased to share our latest work on a rare and indolent form of lymphoma, Duodenal-type Follicular Lymphoma. Mahmoud Aljurf Riad El Fakih Ruah Alyamany | روى اليماني pubmed.ncbi.nlm.nih.gov/39246163/

Join us at the annual Saudi Liver Meeting 2024! Visit our booth to learn more about ACP membership and explore the latest advancements in liver health. See you there! 🩺🤩 زورونا في مؤتمر الكبد السنوي الذي تنظمه الجمعية السعودية لأمراض وزراعة الكبد للاطلاع على أحدث التطورات في

With increasing pola using in frontline, is CD19 bridge to CD19 CAR possible? We think so, with CD19 directed ADC loncastuximab in CIBMTR database #lymsm onlinelibrary.wiley.com/doi/10.1002/jh…

Severe aplastic anemia (SAA) is a disease where the bone marrow doesn’t make enough blood cells. #BMT can cure SAA, but it also can have serious effects on the skin, eyes, digestion, memory, and more. Read more about this BMT CTN study: cibmtr.org/Files/Patient-…

📣 We are proud to announce the new open-access EU CAR-T Handbook, now available in a digital format on our website. GoCART_Coalition European Hematology Association This updated version includes new developments in CAR-T according to the latest clinical data and regulatory advancements.

💡 Have you seen this recent publication in Bone Marrow Transplantation? 📰 Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice

Had a wonderful experience listening to Mehdi Hamadani, MD talk in #Kansas! Simple, crisp, and straight to the point. Always a pleasure to hear him speak! #Auto role in #lymphoma

🌟 Join us in Lille for CAR T day, the 9th International Symposium on CAR T cells🌟 From September 11-12, 2025, the #CARTday will have the immense pleasure of welcoming you to one of France's most iconic cities: Lille! ✨ Why choose Lille? A center of excellence in oncology:

🤔 Did you know? 💡CAR T cell therapy (Chimeric Antigen Receptor - T) is a groundbreaking cellular immunotherapy strategy, rapidly advancing to fight cancer. CAR T cells are genetically modified T lymphocytes designed to recognize and destroy cancer cells. 👁️‍🗨️ Here's how it

Kikking off 2nd day of CART-Cell Preceptorship at KFSH&RC Great talks, enriched interactive discussions,very good learning experience and great hospitality Thank to Mahmoud Aljurf Ayman Saad مستشفى الملك فيصل التخصصي ومركز الأبحاث مؤسسة ومركز الحسين للسرطان

Check out our recent reveiw "Programmed death inhibitors in CNS B-cell lymphoma: A literature review " مستشفى الملك فيصل التخصصي ومركز الأبحاث Thanks to Riad El Fakih and boss Mahmoud Aljurf share.google/sCIjA1D40TqGjR…